
Building a Biotech From Zero (Part 2 of 2): Investor Reality, Liquidity Myths & Founder Dynamics
In Part 2, Ray and David continue their deep dive into the realities of early-stage biotech growthâmoving into warrant coverage, investor upside, dilution, and the often-overlooked truth that early equity can be illiquid












